PT Prodia Diacro Laboratories Wins Frost & Sullivan Customer Value Leadership Recognition

PT Prodia Diacro Laboratories, an independent Indonesian Contract Research Organization (CRO), has been recognized by Frost & Sullivan for its outstanding achievements in customer-centric service delivery and operational excellence. The company has received the 2026 Southeast Asian Customer Value Leadership Recognition for its reliable, integrated clinical research ecosystem and commitment to quality, innovation, and long-term sponsor value.

According to Unmesh Lal, Vice President at Frost & Sullivan, Prodia the CRO has excelled in aligning its capabilities with evolving sponsor requirements while executing clinical research programs with quality, consistency, and efficiency. Lal highlighted Prodia the CRO's ability to bring together clinical trial management, laboratory support, site management, regulatory consulting, consumer product clinical assessment, and emerging pharmacovigilance capabilities. This integrated model enables sponsors to simplify study execution while maintaining strong standards of quality and compliance.

Prodia the CRO has established a strong local expertise and a wide network of investigators, key opinion leaders, and research sites through sustained engagement in the local clinical research community. The company has developed at least 10 clinical research units and GCP certification for more than 5,000 physicians, supporting the conduct of over 110 clinical studies actively recruiting participants in Indonesia. These efforts have contributed to the country's broader clinical research readiness.

Erizal Sugiono, Director at PT Prodia Diacro Laboratories, emphasized the company's commitment to continuous innovation. Sugiono stated, "We see innovation as a commitment to continuously improving how clinical research and related services are delivered. Our latest Pharmacovigilance services reflect this commitment, supporting our partners in strengthening safety management and meeting evolving regulatory requirements."

The company's integrated capabilities span regulatory consulting, clinical trial management, site management, central laboratory services, consumer product clinical assessment, and pharmacovigilance services. This integrated model reduces vendor fragmentation, streamlines communication, and enables sponsors to access coordinated support across the clinical research lifecycle.

PT Prodia Diacro Laboratories is positioned to address the increasingly complex requirements of sponsors conducting clinical research across Southeast Asia. The company continues to invest in quality systems, laboratory capabilities, technology-enabled study oversight, strategic partnerships, and specialized services such as pharmacovigilance. This strategic approach has enabled Prodia the CRO to deliver reliable, compliant, and integrated solutions to its clients.

Frost & Sullivan's recognition underscores Prodia the CRO's commitment to delivering measurable customer value and strengthening Indonesia's position in the evolving clinical research landscape. The company's heritage in the Prodia Group, combined with decades of laboratory expertise, provides a strong foundation for supporting increasingly complex clinical development programs.